Axonal neuropathy and demyelinating neuropathy are two fundamentally different ways peripheral nerves can break down, and the distinction matters because it shapes everything from diagnosis to treatment to long-term outlook. In axonal neuropathy, the nerve fiber itself degenerates, usually starting at its farthest tip and working backward. In demyelinating neuropathy, the insulating sheath wrapped around each fiber is stripped away, slowing or blocking the electrical signals the nerve carries. In practice, the line between the two is not always clean, since demyelinating disease can eventually damage axons too, and vice versa.
What Actually Goes Wrong in Each Type
A peripheral nerve is like a bundle of electrical cables. Each cable has two parts that matter here: the axon, which is the long conducting wire stretching from the spinal cord to a muscle or skin surface, and the myelin sheath, a fatty insulating layer that wraps around the axon in segments. In axonal neuropathy, the wire itself breaks down. In demyelinating neuropathy, the insulation is lost while the wire initially stays intact.
Axonal damage typically follows a pattern called “dying back” degeneration. The nerve fiber deteriorates from its most distant point and works its way toward the cell body. That is why people with axonal neuropathy usually notice symptoms in their toes and feet first, then their fingers and hands, before anything closer to the trunk is affected. Research using injury models has shown that dying-back degeneration can take two forms: the axon either fragments into small pieces as the internal structure collapses, or it retracts in an organized pull-back toward the cell body.1PubMed. Two distinct types of dying back axonal degeneration in vitro Animal studies have linked this process to disruptions in axonal transport, the internal conveyor belt that moves proteins and energy supplies along the nerve fiber. When that transport fails, the most distant nerve terminals lose their supply first and begin to degenerate, eventually disconnecting from the muscles they serve.2PubMed. Motor deficit in a tauopathy model is induced by disturbances of axonal transport leading to dying-back degeneration and denervation of neuromuscular junctions
Demyelinating damage works differently. Rather than the nerve fiber dying, the Schwann cells that produce and maintain the myelin sheath malfunction or are attacked. In inflammatory neuropathies like Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), macrophages physically strip myelin from axons.3Neurology and Clinical Neuroscience. The role of macrophages in Guillain‐Barré syndrome and chronic inflammatory demyelinating polyneuropathy Schwann cells themselves also participate in myelin destruction through an autophagic process, essentially digesting their own myelin.4Glia. Autophagic myelin destruction by schwann cells during wallerian degeneration and segmental demyelination Without intact myelin, signals slow dramatically or fail to reach their destination at all. A healthy myelinated nerve conducts signals by jumping between gaps in the myelin (saltatory conduction); once the insulation is stripped, that efficient jumping stops and conduction crawls or halts.
Common Causes Behind Each Type
Axonal neuropathies are far more common overall. The biggest driver is diabetes, which causes a length-dependent, predominantly axonal neuropathy that affects millions of people. Chemotherapy drugs, alcohol, HIV, and hepatitis C can also cause distal axonal degeneration.5PubMed Central. Mechanisms of distal axonal degeneration in peripheral neuropathies In many of these cases, the underlying problem is metabolic or toxic: the nerve fiber is being slowly poisoned or starved of what it needs to maintain itself across its full length. That is why the longest fibers, the ones running to the feet, fail first.
Demyelinating neuropathies are less common but tend to be more dramatic when they hit. The classic acute form is Guillain-Barré syndrome, which typically follows an infection and can cause rapid, widespread weakness. The chronic counterpart is CIDP, where the immune system attacks myelin over months or years. Both are considered autoimmune conditions driven by an abnormal immune response against components of the peripheral nerve.6PubMed Central. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP In some CIDP patients, specific antibodies target proteins at the junction between the myelin sheath and the axon, detaching the myelin from the nerve fiber and disrupting conduction.7Neurology and Clinical Neuroscience. The role of macrophages in Guillain‐Barré syndrome and chronic inflammatory demyelinating polyneuropathy There are also inherited causes: Charcot-Marie-Tooth (CMT) disease comes in both demyelinating and axonal forms, making it a useful illustration of the same genetic framework producing either type depending on which gene is affected.
Charcot-Marie-Tooth Disease as a Case Study
CMT is the most common inherited neuropathy, and it neatly divides along the axonal-demyelinating line. The demyelinating forms (CMT1) produce markedly slow nerve conduction velocities because the myelin is abnormal from birth, while the axonal forms (CMT2) show relatively preserved conduction speed but reduced signal strength because the axons themselves degenerate. In a large evaluation of over a thousand patients, roughly two-thirds received a genetic subtype diagnosis. The most frequent subtypes were CMT1A (a demyelinating form caused by a duplication of a gene critical for myelin production), CMT1X, hereditary neuropathy with liability to pressure palsies, CMT1B, and CMT2A. All other subtypes individually accounted for less than one percent of cases. Patients could be sorted into specific groups based on when symptoms began and how much their nerve conduction velocities were slowed.8PubMed Central. Charcot-Marie-Tooth disease subtypes and genetic testing strategies
This is one of the clearest examples of why the axonal-demyelinating distinction is not just academic. In CMT1A, the problem is a myelin gene, and the nerve conduction velocities are uniformly slow across all nerves. In CMT2A, the problem is an axonal maintenance gene, and conduction velocities stay relatively normal even as the patient loses nerve fibers. A neurologist seeing uniformly slow conduction in a young patient with foot deformities is going to think about demyelinating CMT and order a specific set of genetic tests. Normal velocities with low signal amplitudes push the evaluation toward axonal CMT and a different gene panel.
How Doctors Tell Them Apart
Nerve conduction studies are the main tool for separating axonal from demyelinating neuropathy, and the logic is straightforward. When the myelin is damaged, signals travel slowly, so conduction velocity drops. When the axon itself is damaged or lost, the speed may be relatively normal, but the strength of the signal (the amplitude) drops because fewer fibers are contributing. Nerve conduction studies quantify both speed and amplitude, along with related measurements, to build a picture of which process is dominant.9PubMed. Nerve conduction and electromyography studies
In practice, the distinction is not always straightforward. One study found that in axonal neuropathies, conduction slowing was more prominent when recording from small distal muscles (in the foot, for instance) and relatively normal when recording from muscles closer to the spine. In demyelinating neuropathies, conduction was markedly slow regardless of where the recording was made. Comparing proximal and distal recordings turned out to be a simple and reliable way to separate the two types, especially in ambiguous cases where both amplitude and velocity were abnormal.10PubMed. Differentiation between axonal and demyelinating neuropathies: identical segments recorded from proximal and distal muscles
Another complication: amplitude reduction and conduction slowing are correlated in both types of neuropathy, which can blur the lines. In axonal neuropathies, the correlation exists because large, fast-conducting fibers are preferentially lost, which pulls down both speed and amplitude. In demyelinating neuropathies, amplitude drops because signals spread out in time (temporal dispersion) or because secondary axonal degeneration sets in. Because of this overlap, researchers have concluded that amplitude reduction alone is not a reliable way to identify the primary process, and clinicians should focus on other features like conduction block, temporal dispersion, and prolonged distal latencies to identify demyelination.11PubMed. Correlations of nerve conduction measures in axonal and demyelinating polyneuropathies
Conduction block is a hallmark of acquired demyelinating neuropathy. It occurs when the signal simply fails to pass through a demyelinated segment of nerve, so the muscle response is much smaller when the nerve is stimulated above the block than below it. Defining “true” conduction block versus amplitude drop caused by temporal dispersion is surprisingly tricky, and recent work has established nerve-specific cutoff values to help clinicians make that call.12European Journal of Neurology. Defining True Motor Conduction Block in Chronic Immune‐Mediated Demyelinating Neuropathies: A Temporal Dispersion‐Based Electrodiagnostic Approach
Clinical Clues Beyond Electrical Testing
The physical exam can hint at which type of neuropathy is present before any electrodes are placed. Axonal neuropathies tend to produce a “stocking-glove” pattern of numbness, tingling, and burning that starts at the toes and gradually creeps upward. Weakness, if it occurs, also follows this length-dependent pattern, affecting toe and foot muscles before anything else. Reflexes are often preserved early on, especially at the knee and bicep.
Demyelinating neuropathies tend to look different. Because the myelin damage can occur anywhere along the nerve rather than just at the tips, weakness and sensory loss can be more widespread and sometimes patchy or asymmetric. Reflexes tend to be lost early and globally. A study comparing CIDP patients to patients with chronic idiopathic axonal polyneuropathy found that absent reflexes were significantly more common in the demyelinating group, and an absent biceps reflex had the highest sensitivity and specificity for identifying CIDP among the reflexes tested.13PubMed. Diagnostic value of myotactic reflexes in axonal and demyelinating polyneuropathy When reflexes were tested with electromyographic recording in that study, latencies often indicated demyelination even when the clinical reflex exam appeared normal, suggesting that subclinical demyelination can hide behind a seemingly unremarkable bedside exam.
When the Two Types Overlap
The clean axonal-versus-demyelinating split is a useful framework, but the real world complicates it constantly. Demyelinating diseases frequently produce secondary axonal damage over time. CIDP is supposed to be a demyelinating neuropathy, yet neurophysiological analysis of CIDP patients consistently reveals signs of axonal degeneration in motor fibers, including reduced signal amplitudes and changes in motor unit structure that indicate the muscle’s nerve supply has been reorganized. These signs of axonal damage can persist even when patients improve clinically and their demyelinating features get better with treatment.14PubMed Central. Neurophysiological Hallmarks of Axonal Degeneration in CIDP Patients: A Pilot Analysis
This secondary axonal loss matters for prognosis. A study examining long-term outcomes in CIDP found that the amount of axonal damage present at the time of diagnosis predicted disability years later, independent of how much demyelination was present. Over time, demyelination measures improved with treatment, but the axonal damage tended to remain stable. The initial axonal loss served as an independent predictor of long-term disability in regression analysis.15PubMed. Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy In other words, you can fix the myelin, but if the axons have already been lost, the damage sticks.
Pain and Nerve Hyperexcitability
Both axonal and demyelinating neuropathies can produce pain, but the mechanisms overlap in ways that are not obvious. When nerves are injured, whether by axon damage or myelin loss, the remaining nerve fibers undergo membrane remodeling. Sodium channels along the nerve shift in their expression and distribution, and the net effect is hyperexcitability: the nerve fires spontaneously or responds excessively to stimuli. This process contributes to burning pain, shooting sensations, and abnormal sensitivity to touch that characterize neuropathic pain regardless of whether the underlying pathology is axonal, demyelinating, or both.16PubMed Central. Sodium channels and mechanisms of neuropathic pain
For the patient, this means that pain alone does not tell you which type of neuropathy you have. Diabetic neuropathy, which is primarily axonal, can be intensely painful. CIDP, which is primarily demyelinating, can also produce significant pain. The type of pain and the location matter more for diagnosis than the presence or absence of pain itself. Burning in the feet that follows a stocking pattern points toward axonal disease. Deep aching limb pain with proximal weakness points more toward a demyelinating process.
Treatment Differences
This is where the distinction has the most direct practical consequences. Demyelinating neuropathies, especially the immune-mediated ones, are often treatable because the immune attack can be suppressed. Intravenous immunoglobulin and plasma exchange are established treatments for both Guillain-Barré syndrome and CIDP, with well-documented efficacy in randomized trials.17PubMed. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies Cochrane review evidence supports plasma exchange for short-term improvement in CIDP, though patients can deteriorate rapidly after treatment stops, underscoring the need for maintenance therapy in many cases.18PubMed Central. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids are another mainstay for CIDP.
Axonal neuropathies are a much harder therapeutic problem. Available treatments are largely limited to addressing the underlying cause (controlling blood sugar in diabetes, removing the toxic exposure) and managing symptoms, particularly pain. No widely used therapy targets the axonal degeneration itself. As one review put it, existing treatments for axonal peripheral neuropathies control painful symptoms but do not treat the underlying axonal degeneration, and neuroprotective strategies developed for brain diseases may not translate well because the core problem in most peripheral neuropathies is degeneration at the far end of the axon rather than death of the nerve cell body.19JAMA Neurology. Neuroprotection in the Peripheral Nervous System: Rationale for More Effective Therapies This gap is one of the most frustrating aspects of peripheral neuropathy care.
Recovery and Repair
Peripheral nerves have a meaningful ability to recover, which distinguishes them from the brain and spinal cord, but recovery is much easier when the damage is demyelinating rather than axonal. Remyelination can happen relatively quickly once the immune attack stops: Schwann cells can proliferate, wrap new myelin around intact axons, and restore conduction. Multiple signaling molecules participate in this process, and research has shown that a protein called neuregulin 1 promotes the rate of remyelination in early recovery, though other pathways compensate at later stages.20Brain. Axonal neuregulin 1 is a rate limiting but not essential factor for nerve remyelination
Axonal regeneration is a slower and less reliable process. An axon that has degenerated must regrow from the point of damage all the way back to its target, at a rate of roughly a millimeter a day. For a nerve running from the lower spine to the toes, that can mean months to over a year of regrowth, and the newly regenerated axon still needs to find its correct target, get remyelinated, and reestablish functional connections.21Annual Review of Neuroscience. Peripheral Regeneration Recovery from severe axonal damage is often incomplete. This is why demyelinating neuropathies generally carry a better prognosis than axonal ones when the axons have been spared, and why secondary axonal loss in demyelinating disease is such a bad sign.
Emerging Biomarkers
One of the newer developments in distinguishing and monitoring these conditions is the blood test for neurofilament light chain (NfL), a protein released when axons are damaged. In CIDP patients, serum NfL levels were roughly four times higher than in healthy individuals, and levels correlated with clinical disability, spinal fluid protein levels, and the degree of active axonal degeneration seen on nerve biopsy. Patients with specific anti-NF155 antibodies had even higher NfL levels, and both NfL and antibody levels dropped after treatment.22PubMed. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients NfL is not a perfect biomarker for every neuropathy subtype. In anti-MAG neuropathy, a different form of immune-mediated demyelinating disease, NfL did not prove useful, possibly because the disease progresses slowly and produces less acute axonal damage.23Journal of Neurology. Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy
The appeal of a blood-based axonal damage marker is obvious: it could help clinicians detect when a supposedly “demyelinating” neuropathy is quietly destroying axons before disability becomes irreversible. It could also track treatment response in real time rather than waiting for nerve conduction studies to change. The field is still sorting out which neuropathy subtypes it works best for.
When Nerve Biopsy Enters the Picture
Nerve biopsy, typically of the sural nerve at the ankle, is reserved for cases where the diagnosis remains unclear after clinical evaluation and electrical testing. Under the microscope, demyelinating neuropathies produce some characteristic findings. “Onion bulbs,” concentric layers of Schwann cell processes surrounding a nerve fiber, are a hallmark of repeated demyelination and remyelination in CIDP. Inflammatory cell infiltration can be seen, and secondary axonal degeneration is often present alongside clusters of regenerating fibers.24PubMed Central. Relevance of Nerve Biopsy in the Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy—A Systematic Review
The technique used to prepare the biopsy specimen matters for what can be seen. Standard paraffin sections stained with routine dyes are useful for spotting inflammation and vasculitis but are not reliable for detecting subtle axon loss or demyelination. Semithin plastic-embedded sections are much better at evaluating myelinated fiber density, onion bulbs, and regeneration clusters, and are moderately useful for assessing demyelination directly.25Neuromuscular Disorders. 147th ENMC International Workshop: Guideline on processing and evaluation of sural nerve biopsies This is worth knowing because biopsy results labeled “nonspecific” sometimes reflect limitations of the preparation method rather than a true absence of pathology. Despite its invasiveness, biopsy remains the only way to directly visualize whether demyelination, axonal loss, or both are present in a given nerve.
Imaging the Nerves Directly
High-resolution ultrasound and magnetic resonance neurography are increasingly used alongside electrical testing. Ultrasound excels at measuring nerve cross-sectional area and detecting swelling at specific sites, which can point toward focal demyelination or entrapment. MR neurography offers better contrast for deep nerves and can detect changes in the muscles that have lost their nerve supply, which helps identify axonal damage indirectly by showing the downstream consequences. The two techniques are considered complementary rather than competing tools in evaluating peripheral nerve disease.26PubMed Central. Ultrasound versus MR Neurography in Peripheral Nerve Diseases: Complimentary Rather than Competitive! In demyelinating conditions like CIDP, nerve enlargement visible on ultrasound or MRI can confirm widespread myelin pathology and help distinguish it from axonal neuropathies where nerves tend to look thinner rather than swollen.